

SCIENTIFIC REPORTS



OPEN

Fetuin-A as a predictor of sarcopenic left ventricular dysfunction

Received: 21 January 2015

Accepted: 01 May 2015

Published: 10 July 2015

Wei-Ting Chang^{1,2,3}, Wei-Chuan Tsai¹, Chih-Hsing Wu⁴, Yen-Wei Lee⁵, Yun-Lin Tai^{1,2}, Yi-Heng Li¹, Liang-Miin Tsai¹, Jyh-Hong Chen¹ & Ping-Yen Liu^{1,2}

Sarcopenia is an aging condition involving low muscle mass and function. Fetuin-A (FetA) appears to be a factor for body composition remodeling. We hypothesized that age increases FetA levels and deteriorates the myocardial function by affecting diastolic function, especially in people with sarcopenia. We enrolled 541 asymptomatic elderly (≥ 65 years) patients. Compared with non-sarcopenic population, FetA levels were significantly elevated in the ninety-two (17%) patients (79 ± 6 years; male: 34.7%) diagnosed with sarcopenia (621.1 ± 140.7 vs. 697.3 ± 179.6 $\mu\text{g/ml}$, < 0.001). Sarcopenic left ventricular dysfunction (S-LVD) was defined by the coexistence of sarcopenia and systolic impairment (LVEF $< 50\%$) and 23 (4.3%) of them met the criteria. Patients with S-LVD showed relatively reduced systolic heart function, higher end-diastolic pressure and a higher FetA level (all $p < 0.001$) than did those with sarcopenia but without LV dysfunction (S-NLVD). Conversely, in the group without sarcopenia, FetA levels were similar regardless of systolic function. Multivariable logistic regression showed that older age, impaired diastolic function, and higher FetA levels were significantly associated with S-LVD. In conclusion, we found that FetA was significantly higher in elderly patients with sarcopenia, which was associated with impaired diastolic and systolic functions.

Sarcopenia is defined as age-related muscle loss characterized by the involuntary reduction in fatty-free muscle mass, strength, and function^{1,2}. Documented in skeletal muscle and aortic smooth muscle, sarcopenia is associated with a decline in protein synthesis, which causes a decrease in type II fibers and in myosin heavy chains³⁻⁵. Although age-related cardiac changes have been well described in humans and rats^{6,7}, only few literatures determined whether sarcopenia occurs in cardiac muscle⁸⁻¹⁰. Sarcopenia has been recently correlated with several degenerative processes. Some hypotheses have linked it to insulin-like growth factor-1 (IGF-1), nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B), and apoptosis^{3,4}. Notably, in the aging heart an increasing incidence of heart failure has been observed in the elderly (≥ 65 years), especially those with sarcopenia^{6,8,9,11}.

Fetuin-A (FetA), a glycoprotein synthesized in the liver and secreted into the circulation, is a calcification inhibitor as well as a conjunction in insulin resistance¹²⁻¹⁶. It was recently reported to be a main factor in adjusting body composition remodeling in the geriatric population¹⁷. Emerging evidence associates FetA with promoting cardiovascular disease by causing coronary and valvular calcification^{18,19}. In addition, higher FetA levels were found to correlate with poor cardiovascular outcomes, including myocardial infarction and ischemic stroke through the insulin related NF- κ B axis^{20,21}. However, whether increased FetA exacerbates the progression of cardiac dysfunction remains unknown. Therefore, we hypothesized

¹Division of Cardiology, Internal Medicine, College of Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. ²Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

³Division of Cardiovascular Medicine, Chi-Mei Medical Center, Tainan, Taiwan. ⁴Department of Family Medicine, College of Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. ⁵College of Medicine, National Cheng Kung University, Tainan, Taiwan. Correspondence and requests for materials should be addressed to P.-Y.L. (email: larry@mail.ncku.edu.tw)

	Non-Sarcopenia (n = 449, 82.9%)	Sarcopenia (n = 92, 17%)	p-value
Age (years)	75 ± 5	79 ± 6	0.001*
Male (%)	251 (55.9)	32 (34.7)	0.001*
WC (cm)	88.63 ± 9.77	78.73 ± 8.74	0.001*
BMI (kg/m ²)	25.3 ± 3.9	22.37 ± 3.1	0.001*
SBP (mmHg)	135.6 ± 20.8	128.5 ± 19.2	0.003*
DBP (mmHg)	77.7 ± 11.7	73.6 ± 11.3	0.002*
MEDICAL HISTORY (%)			
CKD	76 (16.9)	45 (48.9)	0.001*
Previous stroke	17 (3.7)	3 (3.2)	0.89
CAD	11 (2.4)	2 (2.2)	0.8
Arrhythmia	19 (4.1)	2 (1.6)	0.8
Cancer	11 (2.4)	4 (3.3)	0.37
SEROLOGY PROFILES			
HbA _{1c} (%)	6.1 ± 0.9	6.1 ± 1.1	0.79
TG (mg/dl)	128.6 ± 79.5	113.8 ± 58.2	0.1
Cholesterol (mg/dl)	201.3 ± 36.7	204.1 ± 34.6	0.52
HDL-C (mg/dl)	49.8 ± 12.4	54.4 ± 15.4	0.003*
Total bilirubin (mg/dl)	0.63 ± 0.3	0.61 ± 0.55	0.67
FetA (μg/ml)	621.1 ± 140.7	697.3 ± 179.6	0.0001*
ECHOCARDIOGRAPHIC PARAMETERS			
LVMi (g/M ²)	81.9 ± 20.4	84.2 ± 30.2	0.65
LVEF (%)	68.79 ± 8.6	62.64 ± 9.3	0.007*
E/A	0.79 ± 0.23	0.67 ± 0.32	0.14
E' (m/s)	0.09 ± 0.03	0.075 ± 0.02	0.08
E/E'	7.5 ± 2.1	9.2 ± 4.4	0.001*

Table 1. Clinical and echocardiographic characteristics: comparison between Non-Sarcopenia and Sarcopenia groups. Data are n (%) or mean ± standard error. BMI = body mass index; BW = body weight; CAD = coronary artery disease; CKD = chronic kidney disease (defined by eGFR ≤ 60 ml/min/1.73 m²); DBP = diastolic blood pressure; E/A = peak early filling velocity (E) to peak atrial velocity (A) ratio; E/E' = early mitral inflow velocity to early annular diastolic velocity ratio; FetA = fetuin-A; HbA_{1c} = glycated hemoglobin; HDL-C = high-density lipoprotein cholesterol; LVEF = left ventricular ejection fraction; LVMi = left ventricular mass index; SBP = systolic blood pressure; TG = triglycerides; WC = waist circumference. *p < 0.05.

that age increases FetA levels and deteriorates the myocardial function by affecting global cardiac function, especially in people with sarcopenia.

Materials and Methods

Study Population. Tianliao Township is a suburban community in Kaohsiung County in southern Taiwan. Almost a quarter (23.7%) of the 31,000 residents are older than 65 y/o. The Tianliao Old People (TOP) study²² has been conducted in an aged cohort since 2009 in order to develop better community-oriented primary care services. According to the 2010 census, there were 1,033 elderly men in Tianliao. We did an epidemiological survey using the whole community sampling method in July 2010. After excluding empty houses (n = 269), deaths (n = 21), and non-ambulatory residents (n = 62), only 681 residents were eligible, and 541 residents were enrolled. The response rate was 60.8% and the statistical power was 0.80. This study was approved by the Institutional Review Board of our institute (IRB no: ER-99-111), the methods were carried out in accordance with the approved guidelines. Also, each participant signed the informed consent before they were examined. Anthropometric (e.g., body mass index (BMI)) and medical information, including previous strokes, coronary artery disease, arrhythmia, and cancer, was collected using a questionnaire. Duplicate waist circumference measurements were done on bare skin midway between the lower rib margin and the iliac crest at the end of normal expiration. Diabetes mellitus was defined according to American Diabetes Association 2010 diagnostic criteria and the medical history reported by each participant.

	Non-Sarcopenia (NS) (449/541, 82.9%)		Sarcopenia (S) (92/541, 17.0%)		p-value
	NS-NLVD (n = 442, 81.7%)	NS-LVD (n = 7, 1.3%)	S-NLVD (n = 69, 12.8%)	S-LVD (n = 23, 4.2%)	
Age (years)	75 ± 6	80 ± 6	80 ± 6	79 ± 6	<0.001*
Male (%)	250 (56.6)	1 (14.3)	21 (30.4)	11 (47.8)	<0.001*
WC (cm)	88.3 ± 9.9	93.5 ± 7.8	78.7 ± 8.7	79.0 ± 7.9	<0.001*
BMI (kg/m ²)	25.2 ± 4.0	26.9 ± 2.9	21.9 ± 2.9	23.8 ± 4.2	<0.001*
SBP (mmHg)	135.7 ± 21.3	131.4 ± 11.9	127.0 ± 17.8	134.4 ± 15.8	0.014*
DBP (mmHg)	77.7 ± 11.9	74.3 ± 9.7	73.1 ± 10.7	77.5 ± 11.4	0.027*
CKD	80 (18)	2 (25)	28 (43)	11 (52)	0.001*
Stroke	18 (4)	0 (0)	2 (2.9)	0 (0)	0.95
CAD	10 (2.2)	1 (12.5)	2 (2)	0 (0)	0.24
Arrhythmia	17 (3.8)	1 (14.3)	2 (2.9)	0 (0)	0.36
Cancer	10 (2.2)	0 (0)	2 (2.9)	2 (8.7)	0.006*
HbA _{1c} (%)	6.1 ± 0.9	5.7 ± 0.1	6.1 ± 1.1	5.9 ± 0.5	0.41
TG (mg/dl)	127.2 ± 78.8	142.1 ± 83.5	127.8 ± 69.4	95.3 ± 37.2	0.28
Cholesterol (mg/dl)	201.5 ± 36.9	190.5 ± 36.1	205.5 ± 34.1	201.1 ± 31.1	0.69
HDL-C (mg/dl)	49.9 ± 12.3	48.4 ± 10.8	53.3 ± 16.6	56.4 ± 13.9	0.034*
Total bilirubin (mg/dl)	0.62 ± 0.27	0.58 ± 0.25	0.64 ± 0.41	0.62 ± 0.48	0.4
FetA (µg/ml)	620.5 ± 142.2	604.9 ± 104.3	664.3 ± 163.8	788.2 ± 170.2	<0.001*
LVMI (g/M ²)	81.4 ± 19.9	94.4 ± 18.2	81.4 ± 19.7	104.2 ± 45.1	0.073
LVEF (%)	69.1 ± 7.9	49.6 ± 1.1	68.7 ± 8.2	44.5 ± 5.9	<0.001*
E/A	0.8 ± 0.31	0.6 ± 0.2	0.7 ± 0.4	0.6 ± 0.11	0.07
E' (m/s)	0.09 ± 0.03	0.07 ± 0.02	0.08 ± 0.02	0.06 ± 0.03	0.02*
E/E'	7.6 ± 2.1	8.6 ± 4.6	8.2 ± 2.4	11.4 ± 4.3	<0.001*

Table 2. Clinical and echocardiographic characteristics: comparison between non-sarcopenic non- left ventricular systolic dysfunction (NS-NLVD), non-sarcopenic left ventricular systolic dysfunction (NS-LVD), sarcopenic non- left ventricular systolic dysfunction (S-NLVD), sarcopenic left ventricular systolic dysfunction (S-LVD) groups. Data are n (%) or mean ± standard error. For other abbreviations, see Table 1. *p < 0.05.

Laboratory Methods. After the participants had fasted for at least 8 hours, peripheral blood samples were collected from them and centrifuged at 3,000 rpm for 15 minutes at 4 °C. The samples were frozen and sent to a central laboratory for analysis. Serum FetA was determined by an ELISA method (intra-assay CV of 2.7%, interassay CV of 3.2%; Biovendor Laboratory Medicine, Brno, Czech Republic). The minimum detectable dose of FetA is 9.38 ng/ml.

Definition of Sarcopenia. To define sarcopenia in this cohort study, we measured skeletal muscle mass (SMM) using a bioelectrical resistance system (BioScan 920; Maltron, Rayleigh, Essex, UK), a convenient and radio-free tool with an operating frequency of 50 kHz at 800 mA. Participants were supine on a non-conducting surface with their arms abducted away from their trunk and their legs slightly separated for 5 minutes. Four electrodes and cables were attached to their right hand and ankle. When the measurements stabilized, the analyzer displayed resistance directly and immediately. SMM was calculated using the BIA equation described elsewhere²:

- $SMM = [(Ht^2/R \times 0.401) + (gender \times 3.825) + (age \times -0.071)] + 5.102$
- Skeletal muscle index (SMI) = SMM/Ht^2

For the associated units: height in cm; resistance in ohms; gender (51 men, 50 women); and age in years. Absolute SMM was converted to an SMI by dividing it by height in square meters (SMM/Ht^2). Based on previous reference, the normal range of the SMI was defined as above 7.23 for men and above 5.67 for women²².

Sarcopenia was defined using the criteria of the European Working Group on Sarcopenia in Older People (EWGSOP)² in 2010 as presenting 3 of the following components: (1) loss of muscle mass: an SMI of ≥ 2 standard deviations (SDs) less than the normal gender-specific mean. In the studied population, an SMI < 7.23 in men and 5.67 in women meant being assigned to the sarcopenic group; (2) low muscle




Figure 1. Higher level of fetuin-A (FetA) was associated with sarcopenic subjects, especially with systolic dysfunction. (A) serum levels of FetA ($\mu\text{g}/\text{mL}$) and (B) diastolic dysfunction ($E' < 8 \text{ cm/s}$ and $E/E' > 8$) prevalence rate in the groups without sarcopenia and left ventricular systolic dysfunction (NS-NLVD), without sarcopenia but with left ventricular systolic dysfunction (NS-LVD), with sarcopenia but with non-left ventricular systolic dysfunction (S-NLVD), and with sarcopenia and left ventricular systolic dysfunction (S-LVD). Abbreviations: FetA, fetuin-A; E/E' , ratio of early transmitral flow velocity (E) to early diastolic mitral annulus velocity (e'). * $p < 0.001$; ** $p < 0.01$.

strength: the maximal weight of hand-grasping < 30 pounds in men and < 20 pounds in women; (3) low physical performance: a maximal walking speed $< 0.8 \text{ m/s}$.

Echocardiography. Standard echocardiography was done (Vivid I; GE Vingmed Ultrasound AS, Horten, Norway) using a 3.5-MHz multiphase-array probe based on the recommendations of the American Society of Echocardiography²³. The chamber dimensions and left ventricular (LV) mass were measured using the two-dimensionally guided M-mode method, and the LV ejection fraction (LVEF) was measured using the two-dimensional M mode. Transmitral Doppler flow velocity was obtained from an apical four-chamber view, and peak early filling velocity (E), peak atrial velocity (A), and the E/A ratio were recorded. Early mitral inflow velocity (E) and early annular diastolic velocity (E') were also measured to estimate the LV end-diastolic pressure (E/E'). Both the medial and lateral early annular diastolic velocity values were measured to achieve the average value. Echocardiographic diastolic dysfunction was defined as the coexistence of impaired relaxation ($E' < 8 \text{ cm/s}$ by tissue Doppler) and elevated average LV end-diastolic pressure ($E/E' > 8$)²⁴. To distinguish from the population with preserved LV systolic function, subjects with LVEF below 50% were defined as impaired LV systolic function or LVD²⁵. The systolic and diastolic function of each echocardiographic imaging was analyzed by experienced cardiologists triplicately. Participants who fulfilled both the criteria of sarcopenia and of impaired




Figure 2. Incrementing FetA quartiles positively correlated with sarcopenia, especially with sarcopenic left ventricular systolic dysfunction (S-LVD). (A) sarcopenia; (B) body mass index (BMI) level; (C) left ventricular mass index (LVMI) (by echocardiography); (D) diastolic dysfunction; (E) systolic dysfunction; and (F) S-LVD. * $p < 0.001$; ** $p < 0.01$.

LV systolic function were assigned to the sarcopenic LV dysfunction (S-LVD) group; participants with sarcopenia and preserved systolic function (LVEF $\geq 50\%$) were assigned to the Sarcopenic-non LV dysfunction group (S-NLVD); those without sarcopenia but with impaired systolic function were assigned to the NS-LVD group; and, finally, those without sarcopenia and with preserved systolic function were assigned to the NS-NLVD group.




Figure 3. Fetuin-A (FetA) serum concentrations negatively correlated with left ventricular ejection fraction (LVEF), significantly in the sarcopenic population. (A) all geriatric participants; (B) in the sarcopenic sub-population and (C) in the non-sarcopenic subpopulation.

Statistical Analysis. Data management and statistical analyses were done using SPSS 18.0 (SPSS Inc., Chicago, IL). Continuous variables with a normal distribution (fasting blood sugar, total cholesterol, HDL-C, LDL-C, FetA, waist circumference, height, weight, body fat, and BMI) are expressed as means \pm standard deviation (SD). Other continuous variables with a non-normal distribution (age, hs-CRP level, triglycerides) are expressed as means \pm standard error (SE). Continuous variables were




Figure 4. The percentages of left ventricular systolic and diastolic dysfunction were significantly higher in sarcopenic elders with higher fetuin-A (FetA) level. (A) left ventricular (LV) systolic impairment and (B) LV diastolic dysfunction in the non-sarcopenia and sarcopenia sub-populations according to the higher and lower FetA level. Lower FetA: FetA below the 1st quartile; higher FetA: FetA above the 3rd quartile; LV systolic dysfunction: left ventricular ejection fraction (LVEF) < 50%; LV diastolic dysfunction: coexistence of impaired relaxation ($E_a < 8$ cm/s by tissue Doppler) and elevated left ventricular end-diastolic pressure ($E/E_a > 8$) from echocardiography. * $p < 0.001$; ** $p < 0.01$.

compared using a Student's t test for normally distributed values. Comparisons between categorical variables were made using a κ^2 test. A Spearman partial correlation coefficient between FetA and LVEF was calculated. To validate the association between sarcopenia and heart function, we separated the participants into sarcopenia as well as non-sarcopenia groups and then further classified each based on whether or not LVEF was >50%. Group differences were analyzed using analysis of variance (ANOVA). Significant differences verified using a Tukey post hoc test in single variant analysis were entered into multivariate analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) were assessed using logistic regression. Statistical tests were 2-sided; significance was set at $p < 0.05$. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff values of FetA in patients with and without sarcopenic cardiomyopathy. The best cutoff value was defined as the point with the highest sum of sensitivity and specificity.

Results

Clinical and Echocardiographic Differences between Subpopulations with and without Sarcopenia. Ninety-two (17%, mean age: 79 ± 6 years; male: $n = 32$ (34.7%)) of our 541 patients (mean age: 75 ± 6 years; male: $n = 283$ (52.3%)) were diagnosed with sarcopenia (Table 1). None of them was reported with specific heart failure symptoms. They were significantly older, more were female, had a smaller waist circumference (WC), a lower BMI, and a lower average blood pressure (BP) (all $p = 0.001$).




Figure 5. Power of fetuin-A (FetA) to predict sarcopenia with left ventricular systolic dysfunction. The area under the receiver operating characteristic curves was 0.81 for FetA, 0.61 for diastolic dysfunction, 0.53 for hypertension (HTN), 0.61 for coronary artery disease (CAD), 0.44 for body mass index (BMI), 0.53 for age, and 0.43 for male gender.

Parameter*	Odds Ratio	95% CI	p-value
SARCOPENIA			
Diastolic dysfunction	4.06	1.62–10.15	0.003*
FetA	1.83	1.02–2.55	<0.001*
Age	1.13	1.09–1.00	<0.001*
SBP	0.98	0.97–0.99	0.003*
DBP	0.97	0.94–0.98	0.003*
LVEF	0.95	0.91–0.98	0.008*
BMI	0.70	0.65–0.77	<0.001*
Male	0.34	0.21–0.5	<0.001*
CAD	0.95	0.2–4.3	0.94
SARCOPENIC HEART FAILURE			
FetA	1.71	1.02–2.31	<0.001*
Age	1.07	1.01–1.14	0.02*
Diastolic dysfunction	2.81	0.98–8.02	0.05*
BMI	0.92	0.82–1.04	0.19
SBP	1.0	0.97–1.03	0.83
DBP	1.02	0.97–1.07	0.52
Male	0.80	0.34–1.86	0.6

Table 3. Multivariate analysis predictors for sarcopenia or sarcopenic left ventricular systolic dysfunction by logistic regression. Univariate with $p \leq 0.15$ were recruited to multivariate logistic regression analysis using stepwise mode. (LV dysfunction: LVEF < 50%) CI: confidence interval. For other abbreviations, see Table 1. * $p < 0.05$.

Echocardiography showed preserved E/E'. Their serologic profiles were similar, except for significantly higher HDL-C ($p = 0.003$) and FetA levels ($p < 0.001$) for patients with sarcopenia.

In this cohort, 23 (25%) of the 92 patients with sarcopenia met the S-LVD criteria (Table 2). Significantly more patients in the S-LVD subgroup were male ($p < 0.001$) and had stroke, coronary artery disease (CAD), and arrhythmia prevalence rates that were not significantly different. Echocardiography showed a non-significantly higher left ventricular mass index (LVMI) and a significantly higher estimated

end-diastolic pressure (E/E') in the S-LVD subgroup, which might indicate stiffness of the myocardium or diastolic dysfunction. The serologic profiles showed significantly higher HDL-C ($p = 0.034$) and FetA ($p < 0.001$) levels in the S-LVD subgroup patients. They had the highest E/E' , FetA levels and the lowest E' of the 4 subgroups. In the group with sarcopenia, FetA was significantly ($p < 0.001$) higher in the S-LVD group ($788.2 \pm 170.2 \mu\text{g/ml}$) than in the S-NLVD group (664.3 ± 163.8), but the difference of FetA levels was not significant in the non-sarcopenia group (Fig. 1A).

Our echocardiographic analysis of diastolic function used impaired relaxation ($E' < 8 \text{ cm/s}$ by tissue Doppler) and subsequently developed high left ventricular end-diastolic pressure ($E/E' > 8$) to facilitate the definite diagnosis. Similar to systolic dysfunction, the prevalence of diastolic dysfunction was significantly ($p = 0.001$) higher in the sarcopenia group and highest in the S-LVD subgroup, but the difference between the NS-LVD and NS-NLVD subgroups was not significant (Fig. 1B). This indicates the different effects of FetA on myocardium contractility and relaxation functions in the elderly with and without sarcopenia.

Ischemic cardiomyopathy is a known major predisposing factor for geriatric cardiac dysfunction; however, in our study, by comparing participants with ($n = 13$) and without cardiovascular diseases ($n = 258$), the FetA concentrations were not significantly different (652.6 ± 159.4 and $630.9 \pm 149.6 \text{ mg/L}$, respectively; $p = 0.34$).

Characteristics of FetA in the Geriatric Population. In this geriatric population, the mean value of serum FetA levels was 633.0 mg/L , which was not different by gender (626.1 ± 149.5 ; $640.5 \pm 150.7 \text{ mg/L}$, respectively; $p = 0.19$) (data not shown). To test the pathophysiologic role of FetA in sarcopenia and heart function, we compared 4 subgroups using the quartiles of FetA (Fig. 2A–F). With a similar disease background, the prevalence of sarcopenia and S-LVD increased with incrementing FetA quartiles. To compare the interplay between FetA and heart function, the association between FetA level and LVEF was echocardiographically analyzed. Interestingly, although the LVEF value was not strongly correlated with the increased quartiles of FetA in the entire study population, the LVEF value was significantly negatively correlated with the FetA level in the sarcopenic group ($R^2 = 0.45$, $p < 0.001$), but not in the non-sarcopenic group ($R^2 = 0.15$, $p = 0.2$) (Fig. 3A–C), which implied the importance of the co-existence of sarcopenia in the link between FetA and LV dysfunction.

To determine whether FetA levels are different in the elderly with and without sarcopenia, the percentages of “higher FetA level” ($>75\%$ 3rd quartile of the whole population) and “lower FetA level” ($<25\%$ 1st quartile of the whole population) in relationship to LV systolic and diastolic dysfunction were analyzed (Fig. 4A). The prevalence rates of high and low FetA levels were not significantly different for the non-sarcopenia subgroups (53.4% vs. 46.6% , $p > 0.05$), but FetA was significantly higher for patients with sarcopenia (71.1% vs. 28.9% , $p > 0.05$). Moreover, in the non-sarcopenia group, both the high and low FetA levels were associated with the similar percentages of LV systolic dysfunction (22.7% vs. 19.7% , $p > 0.05$). Interestingly, in the sarcopenia group, those with a high FetA level were more significantly associated with higher incidence of LV systolic dysfunction than were those with a low FetA level (64.7% vs. 5.9% , $p < 0.05$). The percentages of diastolic function as well as high and low FetA levels were similar to those in patients with systolic impairment (Fig. 4B). All the results for this analysis implied that the specific role of sarcopenia in FetA is related to the impairment of both systolic and diastolic heart function.

Diagnostic Value of FetA in Sarcopenia and Sarcopenic Left Ventricular Dysfunction. S-LVD was associated with multiple risk factors. A multivariable logistic regression test to determine the independent risk factors showed that, in this cohort, in addition to the known risk factors for sarcopenia, e.g., a reduced waist circumference and a high E/E' value (Table 2), a high FetA level was an independent risk factor for S-LVD (Table 3).

The area under the ROC curve was 0.81 for S-LVD (Fig. 5). For predicting S-LVD, using FetA $>671 \text{ mg/L}$ as a cutoff point, the sensitivity was 65.2% and the specificity was 76.4%. Similarly, a low FetA level ($<512 \text{ mg/L}$) implied a less probability of S-LVD (true negative: 92.3%).

Discussion

In this study, we investigated the effects of sarcopenia, a systemic aging process that seems to present not only the wasting of skeletal muscle, but also of the myocardium. We indicated a new term that describes comorbid sarcopenia and systolic heart dysfunction: “sarcopenic LV dysfunction (S-LVD)”. We found that sarcopenic patients were prone to a relatively reduced systolic heart function, increased end-diastolic pressure and a higher FetA level.

Compared with other Asian geriatric studies, we found a relatively lower prevalence of sarcopenia⁶. According to the literature, muscle strength decline is typically observed in 20–40% of older people by their sixties and in more people over 70 years old^{1,2}. The estimated prevalence of sarcopenia in older men and women worldwide varies from 3% to 30%, and even approached 50% in those over 75 years old². Our survey data showed a 17% prevalence rate of sarcopenia in this Asian geriatric community. One possible reason might be the ethnic variation between Caucasian and Asian population. The other explanation for the discrepancy in this study may be attributable to the rural agricultural lifestyle lived by most residents of Tianliao Township: they are more physically active than most urban residents.

Regarding the biomarkers evaluation, people over 65 had lower albumin levels as well as less insulin resistance and dyslipidemia. Interestingly, in the echocardiographic study, they had a higher E/E'. These results highlighted the effect of aging not only presented in skeletal muscle, but also in nutrition, kidney as well as the cardiac function.

More recently, we also documented stiffer characteristic hearts over the elderly population than the younger's hearts²⁶. Age-associated cellular and molecular mechanisms involve cardiomyocyte function, especially apoptosis, alterations of neurohormonal regulation, and changes in the extracellular matrix²⁷. In an aging heart animal model, intracellular lipid accumulation and a decrease in glycogen storage were both found in senescent mice⁷. A mathematical simulation also indicated that several changes in LV dimension, collagen deposition, wall stress, and wall stiffness precede LV dysfunction⁷. In humans, many mechanisms have been proposed for the aging process, including mitochondrial function changes, senescence adaptation, and telomerase shortening²⁸. Quantitative studies have shown that a continuous loss of myocytes is accompanied by reactive hypertrophy of the remaining cells in the aging heart^{7,29}.

In the present study, we indicated that an increase in the serum FetA level was associated with gradually declined heart function. Also, FetA was specifically elevated in the sarcopenic population with impaired LVEF, which was absent in the non-sarcopenic population. The function of FetA in human beings remains controversial, especially with the respect to sarcopenic hearts. FetA, previously recognized as a calcification inhibitor, has been discovered to play different roles in various fields. Despite the reasonable suspicion of its involvement in diastolic dysfunction, FetA knockout mice showed significant myocardial stiffness, cardiac remodeling, and diastolic dysfunction^{13,18,30}. Conversely, overexpression of FetA prevented ectopic mineralization of connective tissues in a mouse model¹². Notably, sarcopenia was correlated with chronic inflammation. Higher expression of IGF-1 and NF- κ B frequently presented in sarcopenic patients^{3,4}. FetA acts as both a calcium inhibitor and a conjunction of fat related inflammation^{12–16,21}. One recent study reported the association of higher FetA levels not only with a higher incidence of subclinical inflammation, metabolic syndrome, and coronary artery calcification, but also with poor outcomes in myocardial infarction and acute ischemic stroke²¹. Therefore, the behavior of FetA may vary in specific populations, like sarcopenic elders.

In our study, compared with the non-sarcopenia group, the sarcopenic group tended to have a higher concentration of FetA, which was associated with a relatively lower LVEF. This implied a possible link between the activation of FetA and sarcopenia-related systolic as well as diastolic dysfunction. Also, by comparing participants with and without CAD, the averaged FetA levels were similar. The similar levels of FetA between these two groups implied that the changes of FetA probably derived from the aging heart instead of through the process of coronary artery disease. However, whether the increased level of FetA was the reason contributing to the myocardial stiffness or it was the result of a compensatory feedback to relieve the rigidity remains unknown. Further investigations are required to identify the character of FetA in the aging heart.

Our study has some limitations. The older participants may hardly reflect the general population and cardiac dysfunction was defined by echocardiographic parameters while clinical symptoms were lacking.

Conclusion

FetA expression was significantly higher in the elderly Asian population with sarcopenia, especially when their heart diastolic and systolic functions were impaired.

References

- Patel, H. P. *et al.* Prevalence of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older People (EWGSOP) definition: Findings from the Hertfordshire Cohort Study (HCS). *Age Ageing*. **42**, 378–384 (2013).
- Cruz-Jentoft, A. J. *et al.* European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing*. **39**, 412–423 (2010).
- Sakuma, K. & Yamaguchi, A. Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. *J Cachexia Sarcopenia Muscle*. **3**, 77–94 (2012).
- Anker, M. S., Von Haehling, S., Springer, J., Banach, M. & Anker, S. D. Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. *Int J Cardiol*. **162**, 73–76 (2013).
- Ryall, J. G., Schertzer, J. D. & Lynch, G. S. Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. *Biogerontology*. **9**, 213–228 (2008).
- Chin, S. O. *et al.* Sarcopenia is independently associated with cardiovascular disease in older Korean adults: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2009. *PLoS One*. **8**, e60119 (2009).
- Lin, J. *et al.* Age-related cardiac muscle sarcopenia: Combining experimental and mathematical modeling to identify mechanisms. *Exp Gerontol*. **43**, 296–306 (2008).
- Fülster, S. *et al.* Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). *Eur Heart J*. **34**, 512–9 (2013).
- Von Haehling, S., Steinbeck, L., Doehner, W., Springer, J. & Anker, S. D. Muscle wasting in heart failure: An overview. *Int J Biochem Cell Biol*. **45**, 2257–65 (2013).
- Florea, V. G. *et al.* The cardiac component of cardiac cachexia. *Am Heart J*. **144**, 45–50 (2002).
- Butler, J. *et al.* Health ABC Study. Incident heart failure prediction in the elderly: The health ABC heart failure score. *Circ Heart Fail*. **1**, 125–133 (2008).
- Jiang, Q., Dibra, F., Lee, M. D., Oldenburg, R. & Uitto, J. Overexpression of fetuin-a counteracts ectopic mineralization in a mouse model of pseudoxanthoma elasticum (abcc6(-/-)). *J Invest Dermatol*. **130**, 1288–1296 (2010).

13. Seto, J. *et al.* Accelerated growth plate mineralization and foreshortened proximal limb bones in fetuin-a knockout mice. *PLoS One*. **7**, e47338 (2012).
14. Pal, D. *et al.* Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. *Nat Med*. **18**, 1279–1285 (2012).
15. Lorant, D. P. *et al.* Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. *Diabetes Care*. **34**, 156–161 (2011).
16. Ou, H. Y. *et al.* Endoplasmic reticulum stress induces the expression of fetuin-a to develop insulin resistance. *Endocrinology*. **153**, 2974–2984 (2012).
17. Ix, J. H. *et al.* Health Aging and Body Composition Study. Fetuin-A and change in body composition in older persons. *J Clin Endocrinol Metab*. **94**, 4492–4498 (2009).
18. Merx, M. W. *et al.* Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. *J Am Soc Nephrol*. **16**, 3357–3364 (2005).
19. Lim, P. *et al.* Usefulness of fetuin-a and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes. *Am J Cardiol*. **111**, 31–37 (2013).
20. Heinrichsdorff, J. & Olefsky, J. M. Fetuin-A: the missing link in lipid-induced inflammation. *Nat Med*. **18**, 1182–3 (2012).
21. Weikert, C. *et al.* Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. *Circulation*. **118**, 2555–2562 (2008).
22. Chang, C. S. *et al.* Smoking, habitual tea drinking and metabolic syndrome in elderly men living in rural community: the Tianliao Old People (TOP) Study 02. *PLoS One*. **7**, e38874 (2012).
23. Lang, R. M. *et al.* Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr*. **18**, 1440–1463 (2005).
24. Oh, J. K., Park, S. J. & Nagueh, S. F. Established and novel clinical applications of diastolic function assessment by echocardiography. *Circ Cardiovasc Imaging*. **4**, 444–455 (2011).
25. Doherty, T. J. Invited review: Aging and sarcopenia. *J Appl Physiol*. **95**, 1717–1727 (2003).
26. Chang, W. T. *et al.* Characterization of aging-associated cardiac diastolic dysfunction. *PLoS One*. **9**, e97455 (2014).
27. Dai, D. F., Chen, T., Johnson, S. C., Szeto, H. & Rabinovitch, P. S. Cardiac aging: from molecular mechanisms to significance in human health and disease. *Antioxid Redox Signal*. **15**, 1492–1526 (2012).
28. Khan, R. & Sheppard, R. Fibrosis in heart disease: understanding the role of transforming growth factor- β , in cardiomyopathy, valvular disease and arrhythmia. *Immunology*. **118**, 10–24 (2006).
29. Anversa, P., Hiler, B., Ricci, R., Guideri, G. & Olivetti, G. Myocyte cell loss and myocyte hypertrophy in the aging rat heart. *J Am Coll Cardiol*. **8**, 1441–1448 (1986).
30. Kim, M. K. *et al.* Vitamin D deficiency is associated with sarcopenia in older Koreans, regardless of obesity: the Fourth Korea National Health and Nutrition Examination Surveys (KNHANES IV) 2009. *J Clin Endocrinol Metab*. **96**, 3250–3256 (2011).

Acknowledgements

This research was supported in part by the Headquarters of University Advancement at the National Cheng Kung University; Health Promotion Program: Blood Pressure Control from Health Promotion Administration, Ministry of Health and Welfare, Taiwan, ROC; grants from National Science NSC101-2314-B-006-075-MY2, MOST 103-2628-B-006-002-MY4 and grant from National Cheng Kung University Hospital (2012–2015, P.Y.L.). The investigator (P.Y.L.) was granted by “A Landmark Project to Promote Innovation & Competitiveness of Clinical Trials by the Excellent Clinical Trial and Research Center in National Cheng Kung University Hospital, Ministry of Health and Welfare, Taiwan.”

Author Contributions

Conceived and designed the experiments: W.T.C., W.C.T., C.H.W., Y.W.L., Y.L.T., Y.H.L. and P.Y.L. Collected and analyzed the data: W.T.C., L.M.T., J.H.C. and P.Y.L. Prepared the Tables and Figure: W.T.C. and P.Y.L. Wrote the paper: W.T.C. and P.Y.L. All authors reviewed the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Chang, W.-T. *et al.* Fetuin-A as a predictor of sarcopenic left ventricular dysfunction. *Sci. Rep.* **5**, 12078; doi: 10.1038/srep12078 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>